Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080772 | 0.80 | CNR2 (0.51) | CNR2KDM4CNAMPTACVR1BTGFBR1 | |
| SCHEMBL12261505 | 0.79 | TGFBR1 (0.60) | CNR2NAMPTACVR1BTGFBR1 | |
| SCHEMBL19523059 | 0.78 | TGFBR1 (0.53) | CNR2KDM4CALDH1A1ACVR1BTGFBR1 | |
| SCHEMBL4649654 | 0.76 | CNR2 (0.59) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12261441 | 0.76 | MKNK1 (0.44) | KDM4CALDH1A1ACVR1BTGFBR1 | |
| SCHEMBL27021657 | 0.76 | KCNA5 (0.52) | CNR2CNR1HTR4 | |
| SCHEMBL5078982 | 0.74 | L3MBTL1 (0.57) | CNR2CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL22583343 | 0.73 | THRB (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL28064903 | 0.73 | MEN1 (0.42) | KDM4CKDM4EACVR1BTGFBR1 | |
| SCHEMBL4649254 | 0.72 | CNR2 (0.62) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | CNR2 1/4885CNR1 2/4885KDM4C 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.